Novartis announces Russian regulatory approval for Gilenya®, a once-daily oral multiple sclerosis therapy and first in a new class Novartis Accessed on 4 Jan 2012 from http://www.novartis.com/newsroom/media-releases/en/2010/1443688.shtml. CommentRecommendBookmarkWatch